News Enhertu scores again in early breast cancer AstraZeneca and Daiichi Sankyo are eyeing regulatory filings for Enhertu in early breast cancer after a second phase 3 trial delivers.
News Lilly brings second oral SERD to market for breast cancer Lilly's Inluriyo is the second oral SERD to reach the US market for ESR1-mutated breast cancer, setting up a market tussle with Menarini's Orserdu.
News Roche's oral SERD comes good in 2nd-line breast cancer trial Roche has staked a claim to use its oral SERD giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status.
News Lilly raises stakes in Novartis battle with Verzenio data Armed with new survival data for Verzenio in early breast cancer, Lilly hopes to keep the drug's nose in front of a fast-growing rival from Novartis.
News AI picks up interval breast cancers missed by scans An AI could help to detect aggressive interval breast cancers that are diagnosed in between routine screening appointments, say US researchers.
News Celcuity eyes big market opportunity after breast cancer win Celcuity shares rocket on a big win for its lead drug gedatolisib in advanced breast cancer, catapulting its value to almost $1.4 billion.
News NHS to offer Wegovy to a million more people in England The NHS in England will make Novo Nordisk's Wegovy available to around 1.2m people in order to reduce their risk of heart attacks and strokes.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
